Characterisation of human kallikrein 6/protease M expression in ovarian cancer
- PMID: 15305183
- PMCID: PMC2364785
- DOI: 10.1038/sj.bjc.6602041
Characterisation of human kallikrein 6/protease M expression in ovarian cancer
Erratum in
- Br J Cancer. 2005 Mar 14;92(5):983
Abstract
Kallikrein 6 (hK6, also known as protease M/zyme/neurosin) is a member of the human kallikrein gene family. We have previously cloned the cDNA for this gene by differential display and shown the overexpression of the mRNA in breast and ovarian primary tumour tissues and cell lines. To thoroughly characterise the expression of this kallikrein in ovarian cancer, we have developed a novel monoclonal antibody specific to hK6 and employed it in immunohistochemistry with a wide range of ovarian tumour samples. The expression was found elevated in 67 of 80 cases of ovarian tumour samples and there was a significant difference in the expression levels between normal and benign ovarian tissues and the borderline and invasive tumours (P<0.001). There was no difference of expression level between different subtypes of tumours. More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 is an early phenomenon in the development of ovarian cancer. Quantitative real-time reverse transcription-polymerase chain reactions also showed elevated kallikrein 6 mRNA expression in ovarian tumours. Genomic Southern analysis of 19 ovarian tumour samples suggested that gene amplification is one mechanism for the overexpression of hK6 in ovarian cancer.
Figures



Similar articles
-
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis.Br J Cancer. 2002 Nov 18;87(11):1287-93. doi: 10.1038/sj.bjc.6600623. Br J Cancer. 2002. PMID: 12439719 Free PMC article.
-
Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma.Clin Biochem. 2000 Oct;33(7):579-83. doi: 10.1016/s0009-9120(00)00182-x. Clin Biochem. 2000. PMID: 11124344
-
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.Clin Cancer Res. 2005 May 1;11(9):3320-5. doi: 10.1158/1078-0432.CCR-04-2528. Clin Cancer Res. 2005. PMID: 15867230
-
Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications.Clin Biochem. 2000 Jul;33(5):369-75. doi: 10.1016/s0009-9120(00)00145-4. Clin Biochem. 2000. PMID: 11018688
-
Human tissue kallikreins: a family of new cancer biomarkers.Clin Chem. 2002 Aug;48(8):1198-205. Clin Chem. 2002. PMID: 12142373 Review.
Cited by
-
Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.Mol Oncol. 2014 Feb;8(1):68-82. doi: 10.1016/j.molonc.2013.09.003. Epub 2013 Oct 1. Mol Oncol. 2014. PMID: 24120346 Free PMC article.
-
Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.Tumour Biol. 2012 Oct;33(5):1375-83. doi: 10.1007/s13277-012-0385-4. Epub 2012 Apr 3. Tumour Biol. 2012. PMID: 22477710
-
KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.Mol Oncol. 2016 Aug;10(7):993-1007. doi: 10.1016/j.molonc.2016.03.008. Epub 2016 Apr 8. Mol Oncol. 2016. PMID: 27093921 Free PMC article.
-
Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer.J Gynecol Oncol. 2012 Jul;23(3):175-81. doi: 10.3802/jgo.2012.23.3.175. Epub 2012 Jul 2. J Gynecol Oncol. 2012. PMID: 22808360 Free PMC article.
-
Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.Cancer Sci. 2007 Jul;98(7):1078-86. doi: 10.1111/j.1349-7006.2007.00495.x. Epub 2007 Apr 24. Cancer Sci. 2007. PMID: 17459052 Free PMC article.
References
-
- Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds) (1988) Current Protocols in Molecular Biology. New York: John Wiley & Sons
-
- Bast RC, Boyer CM, Olt GJ, Berchuck A, Soper JT, Clarke-Pearson D, Xu FJ, Ramakrishnan S (1990) Identification of marker for early detection of epithelial ovarian cancer. In Ovarian Cancer Biological and Therapeutic Challenges, Sharp F, Mason WP, Leake RE (eds). pp 265–275, London, England: Chapman & Hall Medical
-
- Bast RC, Hunter V, Knapp RC (1987) Pros and cons of gynecological tumor markers. Cancer 60: 1984–1992 - PubMed
-
- Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998) CA125: the past and the future. Int J Biol Markers 13: 179–187 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical